Using an inhibitor of JNK, D-JNKI1—in a phase III clinical trial for treating intraocular inflammation resulting from surgery or trauma [42]—Buccarello et al. reported that monthly intraperitoneal injections of D-JNKI1 preserved the RGCL in a mouse model of AD [41]. This evidence concerns the gene MAPK8 and Alzheimer disease.